Deep learning

Heavy-chain-only antibody
#3DEXPERIENCE cloud platform #Affinity maturation #Antibodies #BIOVIA #Deep learning #Webinar

Register now: Antibody affinity maturation through deep learning and mutation analysis

This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More

#News

#3DEXPERIENCE cloud platform #Affinity maturation #Antibodies #BIOVIA #Deep learning #Webinar

On demand webinar explores explainable affinity maturation

This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More

#News

Monoclonal antibody
#3DEXPERIENCE cloud platform #Affinity maturation #Antibodies #BIOVIA #Deep learning #Webinar

Watch now: Deep learning meets physics-based analysis

This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More

#News

#3DEXPERIENCE cloud platform #Affinity maturation #Antibodies #BIOVIA #Deep learning #Webinar

Available now: Webinar on moving towards explainable affinity maturation

This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More

#News

#3DEXPERIENCE cloud platform #Affinity maturation #Antibodies #BIOVIA #Deep learning #Webinar

On demand: Combining deep learning and physics-based mutation analysis

This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More

#News

#3DEXPERIENCE cloud platform #Affinity maturation #Antibodies #BIOVIA #Deep learning #Webinar

Toward explainable affinity maturation: Combining deep learning and physics-based mutation analysis

This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More

Webinar date:
Supported by BIOVIA
#Webinars

#3D deep learning imaging #Deep learning #Drug discovery #Financing #Imaging #Qureight #Series B financing

Qureight closes $20 million Series B financing 

Cambridge data analytics company Qureight has raised $20 million in a Series B financing, led by Molten Ventures, which will support expansion of the Company’s 3D deep learning imaging portfolio, alongside commercial expansion to address demand across key new therapeutic markets for lung and heart diseases.  Existing investors Hargreave Hale… Read More

#News

Human brain
#Artificial intelligence (AI) #Automation #Deep learning #Drug discovery #eBook #Machine learning

eBook: AI – Advancing drug discovery and development

Over the last few years artificial intelligence (AI) has emerged as a key trend and an important area for investment in drug discovery, whether in preclinical research workflows, clinical trial design or regulation. “AI is evolving faster than any other lab technology with new models and… Read More

#News

eBook: AI – Advancing drug discovery and development
#Artificial intelligence (AI) #Automation #Deep learning #Drug discovery #eBook #Machine learning

AI – Advancing drug discovery and development

Over the last few years artificial intelligence (AI) has emerged as a key trend and an important area for investment in drug discovery, whether in preclinical research workflows, clinical trial design or regulation.

#DDW eBooks #Intelligence

Quantum computer
#Artificial intelligence (AI) #Deep learning #Molecular research #Quantum computing #Verseon

Deep quantum modelling: Shifting the drug-discovery paradigm 

Adityo Prakash, CEO of Verseon, introduces a new mathematical approach to computing molecular interactions.  The objective of small-molecule drug discovery is to find binders to target proteins involved in disease processes. However, the discovery and development of novel small-molecule therapeutics remains one of the most resource-intensive endeavors… Read More

#Exclusive Content #Opinion

Neural networks
#Artificial intelligence (AI) #Deep learning #Drug discovery #Interview

How neural networks can advance AI in drug discovery

DDW Editor Reece Armstrong speaks to Adityo Prakash, CEO of Verseon, about AI and deep learning in drug discovery and how neural networks within AI are influencing drug discovery approaches. RA: Could you explain the architectural differences between Verseon’s VersAI’s neural network and deep learning neural networks? AP: The underlying… Read More

#Exclusive Content

#Deep learning #Idiopathic pulmonary fibrosis #Imaging #Phase II trial #Qureight

Deep-learning imaging technology to enhance Phase II trial

Biopharmaceutical company Rein Therapeutics and core imaging laboratory Qureight have announced plans to collaborate on an idiopathic pulmonary fibrosis (IPF) clinical trial.  The companies will integrate Qureight’s deep-learning platform into Rein’s planned Phase II trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide.  … Read More

#News

#Artificial intelligence (AI) #Clinical trial design #Deep learning #Fibrosis #Imaging #Interview

How is deep learning imaging advancing drug discovery for fibrosis?

Diana Spencer speaks to Dr Muhunthan Thillai, CEO at Qureight, about the company’s AI-powered imaging analytics and the technology’s potential in lung diseases and beyond.  DS: Can you provide some background to the company? MT: We are a core imaging laboratory using deep-learning and analytics… Read More

#Exclusive Content

Fibrosis lungs
#Artificial intelligence (AI) #Deep learning #Idiopathic pulmonary fibrosis #Partnership #Phase I trial #Qureight #Remedy Cell

Deep learning provides enhanced imaging analysis in IPF trial

Qureight and biopharmaceutical company Remedy Cell have agreed a partnership to validate RC-0315’s mechanism of action in idiopathic pulmonary fibrosis (IPF).  The primary objective of the RC-0315 Phase Ib clinical study is to measure drug safety and tolerability.   The study’s exploratory objectives will assess the… Read More

#News

Fibrosis lungs
#Avalyn Pharma #Deep learning #Fibrosis #Phase II trial #Qureight

Deep learning to provide insights in pulmonary fibrosis trial 

Qureight and Avalyn Pharma have announced the initiation of a strategic partnership in progressive pulmonary fibrosis, commencing with the ongoing MIST study.  The MIST study is a Phase IIb clinical trial evaluating the safety and efficacy of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF). Read More

#News

London, UK
#Artificial intelligence (AI) #Deep learning #Expansion #London #Recursion #TechBio

Is Recursion’s new London hub an epicentre of drug discovery?

Recursion has announced plans to open a new office in June 2024. The site will provide Recursion and Valence Labs, the company’s artificial intelligence (AI) research engine, with access to European talent and a life science ecosystem from which to work. Chris Gibson, Co-founder and CEO… Read More

#News